title: Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood group, hepatitis B virus and their synergism.
abstract: Little is known about the role of association between ABO blood group and development of extrahepatic cholangiocarcinoma (ECC) through effects on hepatitis B viral (HBV) infection. Our aim was to address this question using a matched case-control study in Southern China.We prospectively analyzed 239 ECC patients, and 478 age- and sex-matched controls in Sun Yat-sen Memorial Hospital of Sun Yat-sen University from 1999 to 2011. Information on ABO blood group, HBV infection and other clinicopathologic factors was collected. Adjusted odds ratios (AORs) and the corresponding 95% confidence intervals (CIs) were computed from unconditional logistic regression models, adjusted for major confounding factors. The estimated AORs were as follows: A blood group, 1.784; HBsAg+/HbcAb+, 1.848 and HBsAg-/HbcAb+, 1.501. The A blood type had a significant effect on modifying the risk of ECC among subjects with HBsAg+/HbcAb+ (AOR 3.795, 95% CI 1.427-10.090). ECC patients with A blood group were more common in younger subjects, and a lower proportion of serum CA-125 and CA19-9 elevation in patients with blood type A was found. Our study suggests an association between A blood type, HBV infection and ECC risk, and a synergism between A blood type and HBV infection in the development of ECC.
authors.affiliation: Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhou
authors.forename: Quanbo
authors.initials: Q
authors.lastname: Zhou
authors.forename: Qing
authors.initials: Q
authors.lastname: Lin
authors.forename: Ruiwan
authors.initials: R
authors.lastname: Chen
authors.forename: Yuanfeng
authors.initials: Y
authors.lastname: Gong
authors.forename: Yimin
authors.initials: Y
authors.lastname: Liu
authors.forename: Min
authors.initials: M
authors.lastname: Yu
authors.forename: Bing
authors.initials: B
authors.lastname: Zeng
authors.forename: Kaiwen
authors.initials: K
authors.lastname: Li
authors.forename: Rufu
authors.initials: R
authors.lastname: Chen
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Li
mesh_terms: D000017:ABO Blood-Group System; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001650:Bile Duct Neoplasms / Q000097:blood / Q000821:virology; D017734:Bile Ducts, Extrahepatic / Q000821:virology; D001789:Blood Group Antigens / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D016022:Case-Control Studies; D002681:China; D018281:Cholangiocarcinoma / Q000097:blood* / Q000821:virology*; D005260:Female; D006509:Hepatitis B / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000017:ABO Blood-Group System; D001789:Blood Group Antigens; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D006514:Hepatitis B Surface Antigens
keywords: ABO blood group; bile duct cancer; epidemiology; hepatitis